Selling Vitamins in Canada: In-Depth Review of Regulations and Licensing Considerations

Vitamins are among the most widely used consumer health products in Canada, yet their regulatory oversight is frequently underestimated. While often perceived as low-risk supplements, vitamins sold for health purposes are regulated as Natural Health Products (NHPs) and are subject to a comprehensive oversight framework administered by Health Canada. This framework governs every stage of a vitamin product’s lifecycle, from formulation and evidence generation through licensing, manufacturing, labelling, importation, advertising, and post-market monitoring. 

For companies seeking to enter or expand within the Canadian vitamin market, regulatory success depends on more than securing a Natural Product Number (NPN). It requires a clear understanding of product classification, evidentiary expectations, site licensing and Good Manufacturing Practices (GMP) obligations, evolving labelling requirements, advertising limitations, and ongoing post-market responsibilities. 

This guide provides an overview of these requirements, with a focus on how they apply specifically to vitamin products and how regulatory decisions made early in development can materially affect approval timelines, compliance sustainability, and long-term market access. 

How Vitamins Are Regulated in Canada 

In Canada, NHPs are regulated under a dual regulatory model that includes both pre-market authorization and post-market oversight. This means regulatory responsibilities do not end once a product is approved. Manufacturers, importers, and product licence holders are responsible for meeting defined requirements before a product enters the market and for maintaining compliance for as long as the product is sold in Canada. 

This lifecycle-based approach reflects the reality that product safety and compliance must be sustained over time, not assessed only at the point of approval. 

Pre-Market Authorization and Ongoing Obligations 

Before market entry, regulated parties must demonstrate that the product meets Health Canada’s requirements for safety, efficacy, and quality. Once a product is licensed, ongoing post-market obligations apply. These include routine quality control and testing of finished product lots, monitoring and reporting of adverse reactions, and maintaining a documented, operational recall system capable of removing affected product from the market if a risk is identified. 

Together, these controls are designed to ensure that products remain safe and compliant throughout their time on the market, not just at the point of approval. 

Vitamin Supplements as Natural Health Products (NHPs) 

Vitamin supplements are regulated as NHPs and are therefore subject to the pre-market authorization process. All NHPs must obtain an eight-digit NPN before they can be sold in Canada. An NPN is issued only after Health Canada has reviewed the product formulation and confirmed that the medicinal ingredients are safe at the proposed daily dose and that the recommended conditions of use and health claims are supported by acceptable evidence. 

In practice, this assessment evaluates whether the product is appropriate for the intended population and whether the claims are proportionate to the strength of the supporting data. Safety and efficacy form the foundation of this review. 

Quality Standards Under the Natural Health Products Regulations  

Quality requirements are assessed in parallel with safety and efficacy. Under the Natural Health Products Regulations, all NHPs, including vitamin supplements, must be manufactured, tested, and controlled in accordance with established quality standards. This includes, where applicable, testing for heavy metals, microbiological contaminants, and ingredient-specific quality attributes such as identity, purity, and potency. 

At the time of product licensing, applicants must attest that these quality requirements are met and must be able to provide supporting documentation upon request. 

Importation and Post-Licensing Quality Oversight 

Quality compliance continues beyond licensing and becomes particularly important at the point of importation. Each finished product lot imported into Canada must meet the applicable regulatory requirements and relevant pharmacopoeial standards before it can be released for sale. Health Canada and border authorities may request quality documentation at any time, and failure to demonstrate ongoing compliance can result in shipment holds, stop-sale actions, or recalls. 

Continuous Oversight Across the Product Lifecycle 

This integrated regulatory approach ensures that vitamin supplements sold in Canada are not only reviewed prior to approval but are also subject to continuous oversight throughout their commercial lifecycle. For companies operating in this space, understanding both pre-market and post-market obligations is essential to maintaining compliance and protecting long-term market access. 

Different Classes of Vitamin Supplements Sold in Canada  

The pre-market assessment of NHPs is a structured and technically detailed process that requires a thorough understanding of the Natural Health Products Regulations and associated Health Canada guidance. In practice, products are typically pre-assessed prior to formal submission to identify regulatory risks, data gaps, and the appropriate submission pathway before review by Health Canada. This pre-submission assessment is critical, as it determines the application class under which a vitamin product will be filed and, by extension, the scope and type of information required at the time of product licensing. 

NHP Product Licence Applications (PLAs) are categorized into Class I, Class II, or Class III. Classification is primarily driven by the medicinal ingredients and their specifications, including source, dosage, and intended use. However, other factors such as route of administration, dosage form, delivery mechanism, target population, and claim complexity may also influence the final classification. 

Class I Vitamin Product Licence Applications (PLAs) 

Medicinal ingredients must be assessed against Health Canada’s published monographs and the Natural Health Products Ingredients Database (NHPID). Products that fully align with a single applicable monograph, including ingredient identity, source, dosage, and claims, may be submitted as Class I applications. Many basic vitamin-only formulations fall into this category and benefit from a streamlined review process under a Class I category.  

Class II Vitamin Product Licence Applications (PLAs) 

Where additional medicinal ingredients are included, such as herbal extracts, the application may fall under Class II, provided that each ingredient is listed in the NHPID, has an applicable monograph, and the formulation remains fully within all monograph parameters. Class II applications are reviewed using pre-cleared information but require submission of additional documentation beyond that required for Class I applications. 

Class III Vitamin Product Licence Applications (PLAs) 

A Class III application is generally required when a product includes medicinal ingredients, specifications, routes of administration, dosage forms, delivery technologies, or recommended conditions of use that are not fully supported by existing Health Canada monographs, or when the proposed claims extend beyond what can be attested to using pre-cleared information. Class III submissions therefore require additional supporting information beyond the attestation-based pathways and are reviewed using a broader evidence package. 

Under the Natural Health Products Regulations, a PLA must include the information set out in the regulations and, when required, supporting safety and efficacy information appropriate to the product and its recommended conditions of use. Evidence to support safety and efficacy may include, depending on the submission, published scientific literature and other evidence types described in Health Canada guidance for supporting modern health claims.  

Where an applicant does submit clinical study evidence, studies are expected to be relevant to the proposed product conditions of use, including dose, frequency, duration, route of administration, and target population. If an applicant plans to conduct a clinical trial in Canada to generate evidence, Part 4 of the Natural Health Products Regulations applies.  

Accurate classification at the pre-submission stage is, therefore, essential. Misclassification can result in application refusal, information request, or significant delays, making early regulatory assessment a critical component of successful and streamlined vitamin product licensing in Canada. 

Product Licence Application Review Timelines   

In addition to determining the scope of information required, the class of a PLA also informs Health Canada’s applicable review performance standard. These standards establish the target timeframe for completion of the pre-market assessment and the issuance of a regulatory decision, either approval with an NPN or refusal. 

Health Canada Review Performance Standards by Application Class 

All Natural Health Product PLAs are reviewed in accordance with performance standards published by Health Canada, which are linked to the application class: 

These timelines reflect the increasing complexity and evidentiary requirements associated with higher-risk or less monographed products. 

Performance Standards Versus Actual Review Timelines 

It is important to note that these performance standards represent target review timelines rather than guaranteed service levels. Actual review times may be extended, particularly for Class III applications, depending on the complexity of the submission, the quality of the evidence provided, and the need for additional review cycles. 

Delays are most commonly associated with requests for clarification or the need to resolve deficiencies identified during the scientific or administrative review. 

Information Request Notices (IRNs) and Refusals 

During the review process, Health Canada may issue Information Request Notices (IRNs) requesting clarification, additional data, or amendments to the proposed product licence information. Applicants are required to respond within defined timelines to avoid delays or negative regulatory outcomes. 

Health Canada may also issue a refusal if the application does not meet regulatory requirements. Refusals may result from administrative deficiencies, incomplete or inconsistent information, or insufficient evidence to support the proposed safety, efficacy, or quality of the product. 

Issuance and Meaning of an Natural Product Number (NPN) 

Where the submitted application contains complete information and provides sufficient evidence to meet the applicable regulatory requirements, Health Canada will issue an eight-digit NPN. 

Issuance of an NPN does not constitute an endorsement of the product by Health Canada. Rather, it authorizes the sale of the product in Canada under the specific conditions of use, formulation, claims, and labelling parameters set out in the product licence and applicable Canadian regulations. 

Cost Recovery and Fees for Selling Vitamins in Canada 

In addition to meeting technical regulatory requirements, companies selling vitamin supplements in Canada should be aware of Health Canada’s authority to implement cost recovery and fee frameworks for NHPs under the Food and Drugs Act. Cost recovery would allow Health Canada to recover a portion of the costs associated with regulatory activities, such as the review of PLAs, Site Licence applications, and ongoing programme delivery, in a manner similar to other health product sectors. 

Current Status of Cost Recovery for NHPs 

Although Health Canada previously proposed a comprehensive cost recovery model for NHPs, with a targeted implementation date of December 1, 2025, the department has confirmed that this date will not proceed. Because the required regulatory fee order has not been published in Canada Gazette, Part II, cost recovery for NHPs, including vitamins, cannot legally come into force on that date. The initiative is currently paused while Health Canada advances broader regulatory modernization efforts, including risk-based oversight, simplified registration pathways, and updated labelling and post-market controls. 

Planning Considerations for Vitamin Companies 

Although cost recovery is not being implemented as initially proposed, the policy direction toward eventual fee implementation remains active. Health Canada has indicated that cost recovery will be reassessed once regulatory reforms are finalized and the fee structure has been properly published, which will be a prerequisite to any fees becoming enforceable. As a result, companies selling vitamins in Canada should: 

While no mandatory fees are currently in effect for vitamin product licence submissions or site licensing, remaining informed and preparatory planning can help companies manage future transitions and align budgeting, launch timing, and portfolio strategies with emerging regulatory expectations. 

Site Licence Considerations for Selling Vitamins in Canada 

Any party that manufactures, packages, labels, or imports vitamin supplements must hold a valid NHP Site Licence issued by Health Canada. While product licensing focuses on the safety, efficacy, and claims of a specific vitamin formulation, site licensing assesses whether the facilities involved in producing and supplying those vitamins operate in compliance with Good Manufacturing Practices (GMP). 

For vitamin products, site licence requirements are particularly important because compliance is assessed not only at the time of product licensing but throughout ongoing manufacturing and importation activities. 

Site Activities Commonly Associated with Vitamin Products 

Vitamin supplements often involve multiple regulated activities across the supply chain. A Site Licence is required for any site that performs one or more of the following activities for vitamins intended for sale in Canada: 

Each site performing these activities must be covered by a Site Licence that accurately reflects the scope of operations. 

GMP Expectations for Vitamin Manufacturing and Handling 

GMP requirements for vitamin products are designed to ensure consistent product quality and to control risks that are specific to vitamin formulations, including variability in potency, degradation over time, and contamination. Site Licence holders are required to maintain quality systems that control raw material qualification, verify the identity and potency of vitamin inputs, and ensure full batch traceability through detailed production and packaging records. 

These systems must also include finished product testing to confirm vitamin content and, where applicable, compliance with heavy metal and microbiological limits, as well as stability programs that support labelled shelf life and monitor degradation over time. Effective complaint handling and recall procedures are required to enable prompt response to quality or safety concerns. These controls are particularly important for vitamin products, as the use of overages, combined with degradation and cross-contamination risks, can directly affect ongoing compliance with licensed specifications. 

Importer-Specific Responsibilities for Vitamin Products 

Importers of vitamin supplements are subject to additional obligations under the Site Licence framework because they are responsible for the compliance of products manufactured outside Canada. In addition to holding a valid Canadian Site Licence, importers must maintain evidence demonstrating that foreign manufacturing, packaging, and labelling sites operate in accordance with GMP that are equivalent to Canadian requirements. This ensures that vitamin products entering the Canadian market are produced under quality systems comparable to those expected domestically. 

For vitamin products, this evidence typically includes documented quality agreements that clearly define responsibilities for vitamin testing, release, and deviation management, as well as audit reports or inspection histories for foreign manufacturing sites. Importers must also retain certificates of analysis for each imported lot to verify vitamin potency and compliance with contaminant limits, and confirm that the imported product matches the formulation and labelling authorized under the Canadian product licence. Regardless of where manufacturing occurs, the importer remains responsible for ensuring that each lot of vitamins meets all applicable Canadian regulatory requirements prior to release into distribution 

Interaction Between Site Licensing and Vitamin Product Licensing 

Site Licence applications are reviewed independently from PLAs and may be submitted in parallel as part of a broader regulatory strategy. For vitamin products, however, the issuance of a NPN authorizes the product formulation and conditions of use but does not, on its own, permit manufacturing, packaging, labelling, or importation unless all required Site Licences covering those activities are in place and valid. 

As a result, a vitamin product may hold a valid NPN yet remain ineligible for sale if there are deficiencies in site licensing. For example, a vitamin D supplement may be licensed at the product level, but cannot be legally imported if the Canadian importer’s Site Licence does not authorize importation activities or if acceptable GMP evidence is not available for the foreign softgel manufacturer. In practice, misalignment between product licensing and site licensing requirements is a common cause of delayed vitamin product launches, even when product authorization has already been granted. 

Labelling Requirements for Vitamin Products Sold in Canada 

In addition to holding valid product and site licences, all vitamin supplements sold in Canada must comply with the labelling requirements applicable to NHPs. These requirements govern how product information must be presented to consumers and are intended to ensure clarity, consistency, and accuracy across the market. 

Transition to Plain Language Labelling (PLL) 

Canada is currently in a transition period from the former NHP labelling framework to the Plain Language Labelling (PLL) requirements. The PLL framework introduces a more standardized and consumer-focused approach to label presentation. A central feature of the new requirements is the mandatory Product Facts table, which standardizes the display of medicinal ingredients, dosage information, and risk statements to improve readability and comparability for consumers. 

Compliance During the Transition Period 

During the transition period, manufacturers may choose to comply with either the former NHP labelling requirements or the new PLL requirements. However, labels must comply fully with one framework or the other. Mixing elements from both labelling regimes on a single product label is not permitted and may result in non-compliance. Regardless of which framework is selected, manufacturers remain responsible for ensuring that all required product information is presented and communicated in the manner prescribed by the applicable regulations. 

Additional Guidance and Resources 

To learn more about the upcoming labelling requirements for NHPs, including details on the transition period and manner of declaration, please refer to our earlier blog. 

Advertising and Claims Considerations for Vitamin Products 

All advertising and promotional materials for vitamin supplements sold in Canada must remain strictly aligned with the claims and conditions of use authorized in the product licence associated with the issued NPN. For vitamin products, this means that marketing communications may only reference the specific recommended uses, dosage, duration of use, target population, and risk information that were reviewed and approved as part of the licensing process. Claims that extend beyond the approved licence wording, even if supported by scientific literature or permitted in other jurisdictions, may be considered non-compliant under Canadian regulatory requirements. 

Implied Claims and Overall Consumer Impression 

In addition to explicit claims, implied claims are a significant regulatory consideration for vitamin products. Health Canada assesses advertising based on the overall impression conveyed to the consumer, taking into account not only the used text but also imagery, layout, emphasis, and contextual cues. Visual elements such as medical settings, healthcare professionals, diagnostic imagery, or depictions of physiological changes may imply disease treatment or therapeutic outcomes that are not authorized for most vitamin products. 

Use of Imagery, Testimonials, and Comparative Messaging 

Before-and-after imagery, testimonials describing symptom improvement, or endorsements suggesting clinical outcomes may be interpreted as implying efficacy beyond general health maintenance. Comparative statements, educational content, and lifestyle imagery can also raise compliance concerns if they reference clinical conditions, nutrient deficiencies, or physiological markers in a way that suggests disease prevention or treatment. As a result, advertising for vitamin supplements should be reviewed holistically against the approved product licence to ensure that both explicit and implied messaging, including visual presentation, remain within the scope of the authorized NPN and applicable Canadian regulatory requirements. 

Post-Market Vigilance and Risk Management for Vitamin Products 

Once a vitamin supplement has been authorized for sale and placed on the Canadian market, the product licence holder assumes ongoing responsibility for monitoring its safety and quality throughout its commercial lifecycle. Post-market vigilance requirements apply to all NHPs and are particularly relevant for vitamins due to their widespread use, routine long-term consumption, and the sensitivity of certain vitamins to degradation or formulation variability over time. 

Adverse Reaction and Complaint Management 

Licence holders must actively collect, assess, and document adverse reaction reports, product complaints, and other emerging safety or quality signals associated with their vitamin products. Serious adverse reactions must be reported to Health Canada within prescribed timelines. Complaint trend analysis is also critical, as recurring issues such as gastrointestinal intolerance, allergen exposure, potency concerns, or packaging defects may indicate underlying quality or formulation issues requiring further investigation. 

Corrective Actions and Regulatory Notifications 

When post-market monitoring identifies a potential risk, licence holders are expected to take timely and appropriate corrective action. For vitamin products, this may include retesting finished product lots to confirm vitamin potency and contaminant limits, reassessing raw material suppliers, adjusting overages or specifications, or implementing changes to manufacturing or quality controls. Where required, Health Canada must be notified and corrective actions must be documented. Effective post-market vigilance systems allow potential issues to be identified and addressed early, reducing the likelihood that localized concerns escalate into recalls or broader enforcement actions. 

Final Remarks 

Selling vitamins in Canada requires navigating a regulatory framework that is both structured and continuously evolving. From determining the appropriate Product Licence Application class and assembling evidence to securing Site Licences, implementing GMP controls, complying with labelling and advertising requirements, and maintaining robust post-market vigilance systems, regulatory obligations extend well beyond initial product approval. Each element of this framework is designed to ensure that vitamin products placed on the Canadian market remain safe, high quality, and appropriately represented throughout their commercial lifecycle. 

Companies that approach vitamin regulation with a lifecycle perspective, rather than a one-time licensing objective, are better positioned to manage regulatory risk, avoid delays, and maintain market authorization over time. Early classification assessment, alignment between product and site licensing, disciplined quality systems, and careful control of claims and imagery all play a critical role in sustained compliance. As regulatory modernization efforts continue, including potential future cost recovery initiatives and evolving labelling expectations, staying informed and proactive will remain essential for successfully selling vitamins in Canada. 

FAQ 

Can vitamins be sold in Canada without a Natural Product Number (NPN)? 

No. Vitamin supplements sold for health purposes in Canada must hold a valid NPN before they can be legally marketed. An NPN confirms that Health Canada has reviewed the product for safety, quality, and efficacy under the Natural Health Products Regulations. Products sold without an NPN, including those offered online or imported directly to consumers, may be subject to stop-sale actions, seizure, or recall. 

Are online and cross-border vitamin sales treated differently from retail sales? 

No. Vitamins sold to Canadian consumers through e-commerce platforms, brand websites, or online marketplaces are subject to the same regulatory requirements as products sold through brick-and-mortar retail channels. This includes NPN issuance, compliant labelling, site licensing for importation, and advertising controls. Products shipped from outside Canada without meeting these requirements may be detained at the border or subject to enforcement action. 

Can the same vitamin product be sold in Canada and other countries using the same label and claims? 

Not necessarily. Canadian labelling and advertising requirements for vitamins often differ from those in other jurisdictions, including the United States and the European Union. Claims, dosage instructions, risk statements, and label formats must align specifically with the Canadian product licence and applicable NHP regulations. Using a “global label” or foreign-approved claims without modification is a common cause of non-compliance in Canada. 

When are vitamins regulated as foods instead of Natural Health Products? 

While most vitamin supplements are regulated as NHPs, certain vitamin-containing products may fall under the food or supplemented food regulatory frameworks, depending on factors such as format, presentation, claims, and conditions of use. Misclassification can result in rejected submissions or enforcement action. Determining the correct regulatory category early is critical, as the applicable evidence, labelling, and compliance requirements differ significantly. 

What happens if a licensed vitamin product changes after approval? 

Changes to a licensed vitamin product, such as formulation adjustments, supplier changes, manufacturing site changes, or label updates, must be assessed for regulatory impact. Some changes require prior approval through an amendment to the product licence, while others must be documented and retained as part of ongoing compliance. Failure to manage post-approval changes appropriately can place an otherwise licensed product offside with regulatory requirements. 

---

✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.